{"filing":{"accession_number":"0001193125-26-254597","cik":"0001818794","ticker":"DYN","company_name":"Dyne Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"dyn-20260603.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526254597/dyn-20260603.htm"},"events":[{"id":7134,"run_id":6259,"accession_number":"0001193125-26-254597","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Dyne Therapeutics announced full enrollment of the registrational expansion cohort (REC) of its Phase 1/2 ACHIEVE trial for z-basivarsen in DM1 patients, with 71 participants enrolled. The company disclosed material clinical development milestones including planned topline data in Q1 2027 and potential BLA submission for Accelerated Approval in Q3 2027, representing significant progress for its lead program.","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":3932,"accession_number":"0001193125-26-254597","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Dyne Therapeutics announced full enrollment of the registrational expansion cohort (REC) of its Phase 1/2 ACHIEVE trial for z-basivarsen in DM1 patients. This represents a material clinical development milestone for a biotech company's lead program that would affect investor assessment of pipeline progress and regulatory pathway advancement, though it does not fit the more specific event categories (earnings, M\u0026A, executive changes, etc.).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:21:35.304990+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3933,"accession_number":"0001193125-26-254597","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces full enrollment of the Phase 1/2 ACHIEVE trial's registrational expansion cohort (REC) with 71 participants and provides material clinical development milestones for z-basivarsen, including planned topline data in Q1 2027 and potential BLA submission for Accelerated Approval in Q3 2027. While this represents significant clinical progress for a lead candidate, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, or litigation). The announcement would materially affect a reasonable investor's assessment of the company's pipeline advancement and regulatory timeline, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:21:35.304990+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3932,"accession_number":"0001193125-26-254597","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Dyne Therapeutics announced full enrollment of the registrational expansion cohort (REC) of its Phase 1/2 ACHIEVE trial for z-basivarsen in DM1 patients. This represents a material clinical development milestone for a biotech company's lead program that would affect investor assessment of pipeline progress and regulatory pathway advancement, though it does not fit the more specific event categories (earnings, M\u0026A, executive changes, etc.).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:21:35.304990+00:00","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-06-03"},{"id":3933,"accession_number":"0001193125-26-254597","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces full enrollment of the Phase 1/2 ACHIEVE trial's registrational expansion cohort (REC) with 71 participants and provides material clinical development milestones for z-basivarsen, including planned topline data in Q1 2027 and potential BLA submission for Accelerated Approval in Q3 2027. While this represents significant clinical progress for a lead candidate, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, or litigation). The announcement would materially affect a reasonable investor's assessment of the company's pipeline advancement and regulatory timeline, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:21:35.304990+00:00","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-06-03"}]}